Rituximab in renal transplantation

Area of Science:

• Immunology
• Transplantation Medicine
• Pharmacology

Background:

• Rituximab is a chimeric anti-CD20 monoclonal antibody causing B cell depletion.
• While not FDA-approved for renal transplantation, it's widely used in ABO incompatible and HLA antibody incompatible transplantation.
• It's also employed for treating post-transplant lymphoproliferative disorder and acute rejection.

Purpose of the Study:

• To review the current applications, mechanisms, and potential risks of rituximab in renal transplantation.
• To highlight ongoing research into rituximab's role in induction therapy and chronic antibody-mediated rejection.
• To elucidate the impact of B-cells and rituximab on T-cell responses in renal alloresponse.

Main Methods:

• Review of existing literature and clinical evidence regarding rituximab use in renal transplantation.
• Analysis of proposed mechanisms of action, including B cell depletion and modulation of T cell responses.
• Examination of reported adverse events and ongoing clinical trials.

Main Results:

• Rituximab is effective in ABO and HLA antibody incompatible transplantation, post-transplant lymphoproliferative disorder, and acute rejection.
• Emerging evidence suggests rituximab may prevent chronic antibody-mediated rejection.
• Potential risks include infectious complications, cytokine release syndrome, thrombocytopenia, neutropenia, progressive multifocal leukoencephalopathy, and cardiovascular events.

Conclusions:

• Rituximab plays a significant role in managing various complications in renal transplantation, particularly in antibody-mediated settings.
• Further research, including ongoing trials, is crucial to fully understand rituximab's efficacy and safety profile, especially in induction therapy and chronic rejection.
• Understanding B-cell modulation by rituximab is key to advancing renal transplantation outcomes.